In Jim Cramer's "Stop Trading" segment on CNBC's Squawk on the Street program, the famous stock picker mentioned Amgen ...

Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

2025 Revenue Guidance -- Management expects full-year revenue of $30 million to $40 million, with Q4 guidance of $5 million ...

Revenue declined 9.4% year over year, impacted by reduced advertising and customer experience disruptions tied to the ...

Record Revenue -- $14.2 million, up 35% year-over-year and 15% sequentially from Q2 2025. Recurring Revenue -- $6.5 million ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Revenue Guidance -- Management reiterated full-year fiscal 2025 revenue guidance of $26 million to $30 million and set Q4 ...

Net Loss — TMC the metals company ( TMC 8.33%) reported a net loss of $184.5 million (46¢ per share), a widening from $20.5 ...

Shares of On Holding ( ONON +2.14%) shot up over 20% this week, according to data from S&P Global Market Intelligence. The ...

Increase in net loss — CFO Kevin Royal reported net loss widened to $2.6 million or $0.15 per share, compared to a net loss of $1.7 million or $0.10 per share in the prior year period.

Trailing Twelve-Month Core Product Sales -- $37 million, a company record, up from $33.8 million, with distributor and ...

Picky market players weren't impressed by the company's twin beats in its latest reported quarter.